[LCID Study Number: 2018-047]

A Phase-III Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow up Period up to 52 Weeks

The purpose of this study is to confirm (1) how well the study drug works at a single dose of 120 million cells compared to a placebo; and (2) how safe and tolerable the study drug is in patients with fistulizing Crohn’s Disease.

Disease/Condition: Crohn’s Disease

Department: Gastroenterology

Location(s): Lahey Hospital & Medical Center (Burlington)

Primary Contact Email: [email protected]